Suraksha Diagnostic Ltd FY26: The Price of Testing the Limits

Section 1 — At a Glance

Suraksha Diagnostic Ltd’s full-year FY26 results reveal a business expanding its physical infrastructure while absorbing significant margin trade-offs. Revenue from operations reached ₹310.41 crore, marking a 23.11% year-on-year increase from ₹252.09 crore in FY25. This growth was driven by an expanding network footprint, with the total number of diagnostic centers reaching 68 alongside 8 central laboratories. Operating profit (EBITDA) for the year grew 15.84% to ₹98.56 crore. However, the consolidated EBITDA margin compressed by 200 basis points to 31.75% compared to 33.75% in the previous fiscal year.

Profit after tax (PAT) grew by a marginal 1.35% to ₹32.19 crore, down from ₹31.82 crore in FY25, restricted by rising operational overheads, expansion-linked depreciation, and finance costs. For the fourth quarter ended March 31, 2026, revenue stood at ₹81.41 crore with a PAT of ₹6.28 crore. The business model remains heavily concentrated, with West Bengal generating 100% of functional revenue during the fiscal year. Asset productivity shows a stark divergence: mature centers (older than two years) maintained stable operating margins of 36.5%, while newer centers operated at an average EBITDA margin of -5.5%. Capital allocation sub-sectors, such as the new genomics vertical and the 63% acquisition of Fetomat, represent long-term volume plays currently in the pre-operative investment phase.

When physical asset replication outpaces immediate volume absorption, the income statement acts as a temporary shock absorber for long-term network value.

The transition from a dominant state footprint to a regional platform hinges on compressed breakeven execution across high-complexity modalities.

Section 2 — Introduction

Suraksha Diagnostic Ltd, incorporated in 2005, operates an integrated healthcare diagnostic platform combining pathology, radiology, and outpatient medical consultancy services. The company has established a dense regional presence across Eastern India, anchored primarily by its central reference laboratory infrastructure in West Bengal.

Following its initial public offering in December 2024, which raised ₹846 crore through an entire Offer for Sale (OFS), the company’s strategic focus has pivotally shifted toward aggressive physical center expansion. Management has systematically introduced high-complexity verticals, such as molecular diagnostics and next-generation sequencing, to capture incremental wallet-share from walk-in retail clients. The current execution strategy aims to duplicate its structural hub-and-spoke operational layout into adjacent, under-penetrated markets within the North-Eastern cluster.

Section 3 — Business Model: WTF Do They Even Do?

Suraksha Diagnostic runs what it formally titles an “integrated diagnostic ecosystem,” which translates to a corporate assembly line designed to capture patients at every point of medical anxiety. The business model functions on a hub-and-spoke infrastructure. At the core sit 8 high-capacity central and satellite laboratories, surrounded by 68 diagnostic centers and a web of 193 collection collection endpoints.

The revenue mix is split: pathology testing brings in 48.85%, while complex radiology (CT scans, MRIs) commands 44.26%. The remaining 6.89% is squeezed out of outpatient doctor consultations at their integrated polyclinics. Management treats these polyclinic consultation rooms as a captive referral pipeline. By hosting over 1,000 panel doctors who consult on-site, Suraksha creates an internal referral loop. A patient steps into a polyclinic room for a cough, receives a prescription, and is directed straight into the adjacent hallway to get a chest X-ray and a metabolic profile.

The strategy is overwhelmingly consumer-focused, with the Business-to-Consumer (B2C) segment delivering 89.02% of operational revenues. This configuration gives them pricing authority but subjects them to local volume fluctuations. Financially, the entire model is a pure play on local asset density: mature centers run with clear operating efficiencies, while new centers consume corporate cash while waiting for steady patient walk-ins.

Section 4 — Financials Overview

Figures are consolidated, in ₹ crore.

Headline Performance Metrics

The top-line numbers present a healthy surface image. Q4 FY26 revenue scaled to ₹81.41 crore, indicating that the physical volume engine is processing tests at a steady pace. Operating profit tracked this growth, coming in at ₹24.37 crore. However, the lower regions of the profit and loss sheet tell a completely different, structurally heavier story. Net profit for the final quarter contracted to ₹6.28 crore, compressed by a rising cost structure that expansion-heavy strategies inevitably invite.

Did Management Walk